Key result
Pacemaker-derived atrial fibrillation diagnostics led to medication changes in only 0.8% (6 of 728) of patients, demonstrating limited therapeutic impact in routine practice.
Why the study?
Does providing pacemaker-derived AF diagnostic data to referring physicians improve the initiation of anticoagulation or antiarrhythmic therapy in an unselected pacemaker practice?
Observational (n=1,100)
Does providing pacemaker-derived AF diagnostic data to referring physicians improve the initiation of anticoagulation or antiarrhythmic therapy in an unselected pacemaker practice?
Routine pacemaker diagnostics for AF in a general practice rarely lead to therapeutic changes, largely because AF is usually already known or patients are already treated.
Answers are grounded in this paper and cite their sources.
Does not support routine reliance on pacemaker AF diagnostics for therapy changes; leaves open value of targeted alerts in selected populations.
AIM: We aimed to determine the practical value of pacemaker diagnostics for atrial fibrillation (AF) in an unselected general pacemaker practice, specifically workflow and initiation of anticoagulation or antiarrhythmic drug (AAD) therapy. METHODS: We prospectively followed consecutive pacemaker interrogations over a period of 1 year to identify patients with AF (burden from 1% to 99%). We contacted referring physicians with AF details, and then determined whether the information resulted in therapeutic changes. RESULTS: Of the 1,100 pacemakers interrogated, 728 were dual chamber (DDDs) with AF diagnostic capability. AF was recorded in 73 (10%) but seven had limited information, leaving 66 patients; of these, 42 (63%) patients were already anticoagulated and in five (7%) patients, anticoagulation had been stopped because of complications. Initial diagnosis of AF was made by the pacemaker in 17 patients (26% of 66; 2% of 728); four (6% of 66) patients were newly initiated on anticoagulation. Of the 66 patients, 17 patients were already on AADs; 49 (74%) had satisfactory rate control or had other issues; only two (3% of 66; 0.3% of 728) received new AADs. CONCLUSIONS: Of 728 patients with DDD pacemakers, only 17 were newly discovered to have AF, and six (0.8%) had changes in medications based on the pacemaker data. Adding pacemaker-derived data to existing clinical information had little therapeutic impact, due to a combination of cumbersome workflow, and because AF was usually known to practitioners. Developments in automated monitoring systems may provide more accessible and therapeutically useful information.
No takes yet. Share an insight, caveat, or question.
Yedlapati et al. (2014) conducted an observational in Atrial fibrillation (n=1,100). Pacemaker diagnostics for atrial fibrillation was evaluated on Changes in medications (anticoagulation or antiarrhythmic drug therapy) based on pacemaker data. Pacemaker-derived atrial fibrillation diagnostics led to medication changes in only 0.8% (6 of 728) of patients, demonstrating limited therapeutic impact in routine practice.
Synapse has enriched 10 related papers. Consider them for comparative context: